Quintrio
Home

PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS

United-Guardian, Inc.

UG

United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $7.78 – $8.22
Volume 10,019
Market cap $37M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$37.12M
Price / earnings
11.87×
Price / book
3.32×
Price / sales
2.98×
EV / sales
2.87×
EV / EBITDA
10.68×

Profitability

Earnings per share
$0.68
Return on assets
23.26%
Return on equity
27.97%
Dividend yield
6.81%

Liquidity and leverage

Debt / equity
0×
Current ratio
6.5×
Quick ratio
5.92×
Cash ratio
0.73×

Cash flow

Price / cash flow
12.34×
Price / free cash flow
12.62×
Free cash flow
$2.94M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for UG, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$3.49M$3.11M$2.87M$2.96M$2.26M$2.84M$2.48M$2.48M
Cost of revenue$1.62M$1.56M$1.45M$1.63M$1.31M$1.34M$1.12M$1.2M
Gross profit$1.88M$1.55M$1.42M$1.33M$953.07K$1.5M$1.36M$1.28M
Selling, general and administrative$0$0$0$0$0$0$0$0
Research and development$121.83K$124.4K$115.02K$124.28K$117.1K$107.87K$114.39K$131.07K
Total operating expenses$766.37K$791.68K$781.98K$610.75K$738K$801.92K$747.13K$725.2K
Operating income$1.11M$754.13K$642.45K$721.9K$215.07K$695.45K$610.92K$556.38K
Interest expense$72.56K$0$0$0$75.17K$0$0$0
Income before taxes$1.17M$917.61K$1.03M$817.98K$326.48K$790.6K$707.96K$640.81K
Income taxes$242.66K$189.03K$214.24K$168.4K$58.03K$163.78K$147.06K$137.09K
Net income$930.91K$728.58K$818.9K$649.58K$268.44K$626.83K$560.9K$503.72K
Net income attributable to common shareholders$930.91K$728.58K$818.9K$649.58K$268.44K$626.83K$560.9K$503.72K
EBITDA$1.14M$783.49K$671.46K$752.62K$242.37K$720.61K$635.95K$582.71K
Basic earnings per share$0.20$0.16$0.18$0.14$0.06$0.14$0.12$0.11
Diluted earnings per share$0.20$0.16$0.18$0.14$0.06$0.14$0.12$0.11

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

UG Stock Gains 28% After Q3 Earnings Surge Y/Y on Sales Growth

United-Guardian, Inc. (UG) reported third-quarter 2026 net sales of $3.49 million, up 54% year-over-year, with net income surging 247% to $930,912. The company achieved broad-based growth across pharmaceuticals, personal care ingredients, and medical lubricants, while expanding gross margins to 53.7% from 42.1%. Stock has risen 28% since earnings announcement, outperforming the S&P 500.

Investing.com

Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon

Heather Fisher won an annual stock-picking contest with a 287% average return on three picks, primarily due to an 849% gain in Aehr Test Systems. However, Fisher sold most of her AEHR shares before the dramatic climb, missing out on significant gains. The contest had 42 participants, with 18 beating the S&P 500's 23.3% return.

GlobeNewswire Inc.

United-Guardian Reports First Quarter Results

United-Guardian, Inc. reported Q1 2026 sales increased 15.8% to $2.87M and net income rose 45.9% to $0.18 per share, driven by 24% pharmaceutical sales growth (led by Renacidin) and 21% cosmetic ingredient sales growth. The company also recognized $303K in settlement income from a contract manufacturer. Management expects continued growth in 2026 from normalized distributor purchasing patterns and expanded market outreach.

GlobeNewswire Inc.

United-Guardian Reports 2025 Financial Results

United-Guardian, Inc. (NASDAQ:UG) reported a 13% decline in net sales to $10.5M in 2025 from $12.2M in 2024, with net income falling to $2.1M ($0.46 per share) from $3.3M ($0.71 per share). The decline was driven by excess inventory at distributor Ashland Specialty Ingredients, decreased global demand particularly in China due to competition and tariffs, and reduced cosmetic ingredient sales. However, pharmaceutical sales increased 15% and medical lubricants rose 4%, with the company receiving pharmacy benefit manager approvals for Renacidin and entering new distribution agreements.

The Motley Fool

United-Guardian (UG) Q2 Sales Drop 16%

United-Guardian reported a 16.3% revenue decline in Q2 2025, primarily due to weak cosmetic ingredient sales from distributor inventory issues. Medical lubricants and pharmaceutical products showed growth, with management hopeful for cosmetic sales recovery in the second half of the year.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 28, 2026$0.30Aug 4, 2026recurring
Feb 9, 2026$0.25Feb 17, 2026recurring
Jul 25, 2025$0.25Aug 1, 2025recurring
Feb 10, 2025$0.35Feb 18, 2025recurring
Jul 23, 2024$0.35Jul 31, 2024recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.